Practical discussions during ⁦COMy⁩ on how to manage patients with specific complications e.g. dialysis, extramedullary disease, etc. ⁦IACH⁩ ⁦Meral Beksac⁩ ⁦Rafat Abonour⁩ ⁦Florent Malard⁩

The closing lecture of the ⁦COMy⁩

My mentor and colleague Mayo Clinic Dr. Ayalew Tefferi will be honored with the Giants of Cancer Care Award OncLive.com tomorrow. #ASCO25 Dr. Tefferi and I work together as Editors of Blood Cancer Journal He is one of the most influential and amazing educators in medicine.

Thrilled that Dr. Saad Usmani Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Chair of the myeloma program Memorial Sloan Kettering Cancer Center will receive the Giants of Cancer Care Award for Myeloma OncLive.com tomorrow. #ASCO25 Congrats dear friend! Best wishes on behalf of all our myeloma colleagues. Cheers!

Indiana University reception at #ASCO2025 . Proud to work with a fantastic group of past, present, and future colleagues IU Simon Comprehensive Cancer Center Indiana University Hematology/Oncology Fellowship IU_UroOnc Rafat Abonour Christopher Sweeney, MBBS Noah Richardson Robin Zon, MD, FACP, FASCO Ahmad Al-Hader Greg Durm Nasser Hanna Jennifer Schwartz MD FASCO

#ASCO25 #myeloma Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 DRVD is standard of care in transplant ineligible patients

Live from #ASCO25! Our researchers are sharing their latest work and standing proudly by their posters today in Chicago. From lab discoveries to clinical impact, they’re driving cancer research forward. #ResearchCuresCancer ASCO

#ASCO25 #myeloma Attaya Suvannasankha Samer Al Hadidi, MD,MS,FACP @jayaniReena . Discussing current and future therapy therapies in myeloma. Great panel important topics.

The power of cellular immunotherapy ! Impressive results! Congratulations ! ⁦Journal of Clinical Oncology⁩ ⁦IACH⁩ ⁦COMy⁩ ⁦ASCO⁩

MIDAS Trial: MRD-Guided Therapy Post-IsaKRd - The study was designed to understand the role of MRD negativity to guide decision-making around transplant in frontline myeloma. - After Isa-KRd x6, 67% were MRD− at 10⁻⁵. IThese patients were randomized to continue Isa-KRd x 6

#ASCO25 #myeloma Aurore Perrot C. Ola Landgren, M.D. Suzanne Lentzsch, MD, PhD Brandon Blue, MD Francesca Gay and Philippe Moreau. The rode to cure? MRD seems to matter. Longer follow up needed. Great studies presented at the oral session.

Daratumumab = Isatuximab in myeloma; then the Univ of Miami crew finds this - "a third mutation, R140G, conferred selective resistance to Daratumumab, while retaining sensitivity to Isatuximab". I imagine finding these patients will be hard. #mmsm pubmed.ncbi.nlm.nih.gov/40493883/

FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for treatment of relapsed/refractory multiple myeloma in patients who have received at least 4 lines of prior therapy #mmsm ⁦International Myeloma Foundation⁩ ⁦Multiple Myeloma RF⁩ ⁦HealthTree Foundation⁩ pharmacytimes.com/view/fda-appro…

📣 Save the Date! Join us for the 12th World Congress on Controversies in Multiple Myeloma (COMy) 🗓 May 14–17 2026 📍 Paris & Online Cutting-edge science, expert debates & global collaboration See you! Watch the 2025 On-Demand Program comy.cme-congresses.com/program-on-dem… Mohamad Mohty

Rafat Abonour discussing updates in multiple myeloma at IU ASCO REVIEW 2025 IU Simon Comprehensive Cancer Center Indiana University Hematology/Oncology Fellowship IU School of Medicine #ASCO2025

1. I've said this several times before on this platform, but the exact moment I knew that I was going to do everything I could to avoid infection with SARS-CoV-2 was when I read an email in February 2020 confirming that anosmia was a cardinal symptom of Covid-19.

Why not

The cancer center’s Nabil Adra, MD, contributed to the National Comprehensive Cancer Network (NCCN®) Guidelines. Learn more: ow.ly/BuSq50W7jTz. #ResearchCuresCancer #NCIcomprehensive Journal of the @NCCN